Fixed-Duration: A Patient-Captivating Standard of Care in CLL
Talha Munir, PhD
Thomas Kipps, MD, PhD
William Wierda, MD, PhD
MRD Testing to Guide Treatment Considerations in CLL
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
Risk-Stratification in Newly Diagnosed CLL
Mutational Testing to Guide Therapy in CLL: Why and When
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
Combination Therapy for CLL: What Evidence Do We Have?
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
Josep Tabernero, MD, PhD
Sara Lonardi, MD
Zev A. Wainberg, MD
Advancements in GU Cancers: Key Data from AUA 2024
Jason Hafron, MD
Carissa Chu. MD
Advances in Minimally Invasive Screening for Lung Cancer
Julie A. Barta, MD, ATSF
Peter J. Mazzone, MD, MPH, FCCP
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
Thomas F. Patterson, MD, FACP, FIDSA
George Thompson III, MD, FIDSA
Invasive Fungal Infections: More Common Than You Think
Peter G. Pappas, MD, FACP
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.